Background
Renal cell carcinoma (RCC) ranks as the third most common urological
malignancy worldwide, comprising ~2.2% of all cancers. The clear cell subtype,
which accounts for 80–90% of RCC cases, is characterized by a wide spectrum
of survival outcomes. The sex-determining region Y box (SOX) family of
proteins, expressed in multiple cell types, plays a crucial role in regulating cell
differentiation and fate in various physiological contexts. Among them, SOX6
and SOX9 have been implicated in the regulation of carcinogenesis in several
human cancers.
Aim
The primary objective of this study is to investigate the immunohistochemical
expression of SOX6 and SOX9 in clear cell RCC, with a focus on their potential
role in tumor progression and as predictors of patient prognosis and survival.
This retrospective analysis included 50 cases of clear cell RCC. Immunostaining
for SOX6 and SOX9 was performed, and the results were correlated with
clinicopathological features.
Results
SOX6 and SOX9 expression was significantly altered in RCC compared with normal
renal tissue (P |
